FDA approves Glenmark's Clobex Spray generic
Glenmark Pharmaceuticals has received Food and Drug Administration approval for its generic Clobex Spray (clobetasol propionate spray, 0.05%). The drug is a corticosteroid indicated to treat moderate-to-severe plaque psoriasis in patients 18 years old and older.
Glenmark said that it will manufacture its Clobex Spray generic at its Baddi plant in India. The drug's market saw sales of roughly $30.5 million for the 12 months ended January 2018, based on IQVIA sales data.
Glenmark said that it will manufacture its Clobex Spray generic at its Baddi plant in India. The drug's market saw sales of roughly $30.5 million for the 12 months ended January 2018, based on IQVIA sales data.